Selected:

HYSINGLA ER 60MG HYDROCODONE BITATRATE

$360.00$1,460.00

HYSINGLA ER 60MG HYDROCODONE BITATRATE

$360.00$1,460.00

Hysingla ER (hydrocodone bitartrate) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Clear
Add to Wishlist
Add to Wishlist

Description

HYSINGLA ER 60MG HYDROCODONE BITATRATE

 

HYSINGLA ER 60MG HYDROCODONE BITATRATE, Hysingla ER (hydrocodone bitartrate) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Hysingla ER (Hydrocodone bitatrate) extended-release capsules are hard gelatin capsules for oral administration. Hydrocodone bitartrate is an opioid agonist and occurs as fine, white crystals, or as a crystalline powder. HYSINGLA ER 60MG HYDROCODONE BITATRATE

Each Hysingla ER contains either 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, or 50 mg of hydrocodone bitartrate and the following inactive ingredients: sugar spheres NF, hypromellose USP, ammonio methacrylate copolymer NF, silicon dioxide NF, talc USP, polyethylene oxide NF, and povidone USP. The capsule shells collectively contain titanium dioxide, FD&C Blue #1, FD&C Red #40, FDA Yellow iron oxide, FD&C Red #3, FDA Black iron oxide, FDA Red iron oxide, and gelatin.

Limitations Of Use
Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see WARNINGS AND PRECAUTIONS], reserve ZOHYDRO ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
Hysingla ER is not indicated as an as-needed (prn) analgesic.

DOSAGE AND ADMINISTRATION
Important Dosage And Administration Information
Hysingla ER should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain. HYSINGLA ER 60MG HYDROCODONE BITATRATE

Daily doses of Hysingla ER , a single dose of greater than 40 mg, or a total daily dose of greater than 80 mg, are only for use in patients in whom tolerance to an opioid of comparable potency has been established. Patients who are opioid tolerant are those receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid.

Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see WARNINGS AND PRECAUTIONS].
Initiate the dosing regimen for each patient individually, taking into account the patient’s severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse [see WARNINGS AND PRECAUTIONS].
Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy and following dosage increases with ZOHYDRO ER and adjust the dosage accordingly [see WARNINGS AND PRECAUTIONS].
Instruct patients to swallow Hysingla ER capsules whole [see PATIENT INFORMATION]. Crushing, chewing, or dissolving the beads in ZOHYDRO ER capsules will result in uncontrolled delivery of hydrocodone and can lead to overdose or death [see WARNINGS AND PRECAUTIONS].

Hysingla ER is administered orally twice daily (every 12 hours)

Initial Dosage
Use of Hysingla ER as the First Opioid Analgesic (opioid-naïve patients)
Initiate therapy with Hysingla ER with one 10 mg capsule every 12 hours.

Use Of this meds In Patients Who Are Not Opioid Tolerant
The starting dose for patients who are not opioid tolerant is this meds orally every 12 hours. HYSINGLA ER 60MG HYDROCODONE BITATRATE

Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression.

Titration And Maintenance Of Therapy
Individually titrateHysingla ER to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving this meds to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [see WARNINGS AND PRECAUTIONS]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. During chronic therapy, periodically reassess the continued need for opioid analgesics.

Patients who experience breakthrough pain may require a dosage adjustment of ZOHYDRO ER, or may need a rescue medication with an appropriate dose of an immediate-release analgesic. If the level of pain increases after dose stabilization, attempt to identify the source of increased pain before increasing the ZOHYDRO ER dosage. Because steady-state plasma concentrations are approximated within 3 days, ZOHYDRO ER dosage adjustments, preferably at increments of 10 mg every 12 hours, may be done every 3 to 7 days.

 

Dosage Modifications In Patients With Severe Hepatic Impairment
Patients with severe hepatic impairment may have higher plasma concentrations of hydrocodone than those with normal function. Therefore, initiate therapy with 10 mg every 12 hours and titrate carefully, while monitoring for respiratory depression, sedation, and hypotension. No adjustment in starting dose with Hysingla ER is required in patients with mild or moderate hepatic impairment

Discontinuation Of Hysingla ER
Do not abruptly discontinue Hysingla ER . When a patient no longer requires therapy with Hysingla ER , taper the dose gradually, according to the schedule in Table 2, while monitoring carefully for signs and symptoms of withdrawal. If the patient develops these sign or symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both.

Hysingla ER contains hydrocodone bitartrate which is a controlled substance and is controlled under Schedule II of the Controlled Substances Act. Hydrocodone, like all opioids, is liable to diversion and misuse and should be handled accordingly. Patients and their families should be instructed to dispose of any Hysingla ER capsules that are no longer needed.

SIDE EFFECTS
The following serious adverse reactions are discussed elsewhere in the labeling:

  1. Addiction, Abuse, and Misuse
  2. Life-Threatening Respiratory Depression
  3. Neonatal Opioid Withdrawal Syndrome
  4. Interactions with Benzodiazepines and Other CNS Depressants
  5. Adrenal Insufficiency
  6. Severe Hypotension
  7. Gastrointestinal Adverse Reactions
  8. Seizures

Additional information

CHOOSE AN OPTION

180 Tablets, 360 Tablets, 500 Tablets, 90 Tablets

Reviews

There are no reviews yet.

Be the first to review “HYSINGLA ER 60MG HYDROCODONE BITATRATE”

Your email address will not be published. Required fields are marked *

Close Menu
Don`t copy text!
×
×

Cart